Daniel J. Renouf
About
Daniel J. Renouf is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Daniel J. Renouf has authored 188 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 135 papers in Oncology, 82 papers in Cancer Research and 65 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniel J. Renouf's work include Cancer Genomics and Diagnostics (76 papers), Pancreatic and Hepatic Oncology Research (62 papers) and Colorectal Cancer Treatments and Studies (50 papers). Daniel J. Renouf is often cited by papers focused on Cancer Genomics and Diagnostics (76 papers), Pancreatic and Hepatic Oncology Research (62 papers) and Colorectal Cancer Treatments and Studies (50 papers). Daniel J. Renouf collaborates with scholars based in Canada, United States and Italy. Daniel J. Renouf's co-authors include Howard J. Lim, Sharlene Gill, Hagen F. Kennecke, David F. Schaeffer, Winson Y. Cheung, Renata D’Alpino Peixoto, Caroline Speers, Philippe L. Bédard, Neesha C. Dhani and Janessa Laskin and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Daniel J. Renouf
177 papers receiving 3.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Daniel J. Renouf Canada | 29 | 2.0k | 969 | 722 | 686 | 421 | 188 | 3.2k | ||
| Qing Kay Li United States | 28 | 1.3k 0.6× | 1.3k 1.4× | 580 0.8× | 1.2k 1.8× | 326 0.8× | 76 | 3.1k | ||
| Colin D. Weekes United States | 28 | 2.1k 1.0× | 1.4k 1.4× | 758 1.0× | 634 0.9× | 341 0.8× | 144 | 3.5k | ||
| Kun He United States | 27 | 2.0k 1.0× | 835 0.9× | 475 0.7× | 1.3k 1.8× | 230 0.5× | 53 | 3.2k | ||
| Paul Frankel United States | 34 | 1.9k 1.0× | 1.8k 1.8× | 658 0.9× | 967 1.4× | 365 0.9× | 214 | 4.1k | ||
| Marjolijn N. Lub–de Hooge Netherlands | 39 | 2.2k 1.1× | 1.2k 1.2× | 471 0.7× | 962 1.4× | 250 0.6× | 100 | 4.8k | ||
| Paula M. Fracasso United States | 31 | 1.6k 0.8× | 1.0k 1.1× | 380 0.5× | 477 0.7× | 345 0.8× | 109 | 3.0k | ||
| John H. Strickler United States | 29 | 2.1k 1.0× | 941 1.0× | 708 1.0× | 962 1.4× | 404 1.0× | 216 | 3.4k | ||
| Alexander Laird United States | 32 | 1.7k 0.8× | 2.7k 2.8× | 745 1.0× | 1.2k 1.8× | 480 1.1× | 97 | 4.9k | ||
| Christina S. Baik United States | 27 | 2.1k 1.0× | 1.3k 1.3× | 685 0.9× | 1.8k 2.7× | 239 0.6× | 116 | 3.5k | ||
| José Manuel Pérez-García Spain | 26 | 2.0k 1.0× | 1.5k 1.5× | 891 1.2× | 962 1.4× | 164 0.4× | 110 | 3.5k |
Countries citing papers authored by Daniel J. Renouf
Since
Specialization
Citations
This map shows the geographic impact of Daniel J. Renouf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. Renouf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. Renouf more than expected).
Fields of papers citing papers by Daniel J. Renouf
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Daniel J. Renouf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. Renouf. The network helps show where Daniel J. Renouf may publish in the future.
Co-authorship network of co-authors of Daniel J. Renouf
This figure shows the co-authorship network connecting the top 25 collaborators of Daniel J. Renouf. A scholar is included among the top collaborators of Daniel J. Renouf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel J. Renouf. Daniel J. Renouf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Shen, Changxian, Tiantian Cui, Linlin Yang, et al.. (2025). KRAS-induced STN1 (OBFC1) promotes proper CTC1–STN1–TEN1 complex-independent DNA double-strand break repair and cell cycle checkpoint maintenance in pancreatic cancer. Nucleic Acids Research. 53(18).
2.
Karasinska, Joanna M., James T. Topham, Steve E. Kalloger, et al.. (2024). Pancreatic cancer tumor organoids exhibit subtype-specific differences in metabolic profiles. SHILAP Revista de lepidopterología. 12(1). 28–28.
3.
Csizmók, Veronika, Cameron J. Grisdale, Laura Williamson, et al.. (2024). Diagnostic and Therapeutic Implications of a FUS ::TFCP2 Fusion and ALK Activation in a Metastatic Rhabdomyosarcoma. Genes Chromosomes and Cancer. 63(9). e23259–e23259.
4.
Wolfe, Adam R., Tiantian Cui, Amy Webb, et al.. (2024). Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions. Science Advances. 10(9). eadj3551–eadj3551.
5.
Titmuss, Emma, Robert J. Vanner, David F. Schaeffer, et al.. (2024). Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors. Cancer Research Communications. 5(1). 66–73.
6.
Loree, Jonathan M., Emma Titmuss, James T. Topham, et al.. (2024). Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial. Clinical Cancer Research. 30(15). 3189–3199.
7.
Titmuss, Emma, Irene Yu, Erin Pleasance, et al.. (2024). Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors. Current Oncology. 31(4). 1865–1875.
8.
Titmuss, Emma, James T. Topham, David F. Schaeffer, et al.. (2024). Clonal hematopoiesis of indeterminate potential (CHIP), treatment outcomes and adverse events in gastrointestinal cancers: A pooled analysis of clinical trial and real-world data.. Journal of Clinical Oncology. 42(3_suppl). 169–169.
9.
Stathis, Anastasios, Anthony W. Tolcher, Daniel J. Renouf, et al.. (2023). Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors. Investigational New Drugs. 41(3). 380–390.
10.
Hilton, John, et al.. (2023). Abstract P6-10-13: An update to a Phase I trial of CFI-402257, an oral TTK inhibitor, in patients with advanced solid tumors with HER2-negative breast cancer expansion cohorts. Cancer Research. 83(5_Supplement). P6–10.
11.
Chu, Quincy S., Tudor–Eliade Ciuleanu, Rodryg Ramlau, et al.. (2023). Abstract CT202: Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses. Cancer Research. 83(8_Supplement). CT202–CT202.
12.
Titmuss, Emma, Alexandra Pender, James T. Topham, et al.. (2022). The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space. Journal of Molecular Diagnostics. 24(6). 609–618.
13.
Chafe, Shawn C., Frederick S. Vizeacoumar, Geetha Venkateswaran, et al.. (2021). Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors. Science Advances. 7(35).
14.
Chu, Jenny E., Benny Johnson, Van K. Morris, et al.. (2020). Population-based Screening for BRAF V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. Clinical Cancer Research. 26(17). 4599–4605.
15.
Mendis, Shehara, Miguel Alcaide, James T. Topham, et al.. (2020). Integration of Whole-Genome Sequencing With Circulating Tumor DNA Analysis Captures Clonal Evolution and Tumor Heterogeneity in Non-V600 BRAF Mutant Colorectal Cancer. Clinical Colorectal Cancer. 19(2). 132–136.e3.
16.
Tsang, Erica S., Jonathan M. Loree, Janine M. Davies, et al.. (2020). Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases. Canadian Journal of Gastroenterology and Hepatology. 2020. 1–5.
17.
Weinberg, Benjamin A., Daniel J. Renouf, Howard J. Lim, et al.. (2019). NRG1-fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option. Annals of Oncology. 30. iv80–iv80.
18.
Drögemöller, Britt I., Beth Brooks, Jose Gerard Monzon, et al.. (2018). Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients. Clinical Cancer Research. 24(8). 1866–1871.
19.
Ko, Jenny J., Hagen F. Kennecke, Howard J. Lim, et al.. (2015). Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer. Clinical Colorectal Cancer. 15(2). 179–185.
20.
Renouf, Daniel J., et al.. (2009). Küçük Hücreli Dışı Akciğer Kanserinde BCL-2 Ekspresyonu İyi Sağkalım İçin Belirleyicidir. Journal of Thoracic Oncology. 1(1). 39–45.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Qing Kay Li Breakdown of academic impact, for papers by Colin D. Weekes Breakdown of academic impact, for papers by Kun He Breakdown of academic impact, for papers by Paul Frankel Breakdown of academic impact, for papers by Marjolijn N. Lub–de Hooge Breakdown of academic impact, for papers by Paula M. Fracasso Breakdown of academic impact, for papers by John H. Strickler Breakdown of academic impact, for papers by Alexander Laird Breakdown of academic impact, for papers by Christina S. Baik Breakdown of academic impact, for papers by José Manuel Pérez-García